—
C+
C+ The full Closelooknet — membership. Open the C+ overview

BridgeBio Pharma Inc (BBIO) — chart, structure and Closelooknet read

The Closelooknet read

BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for BBIO, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 50, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-02
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sector × region Health care in US: +3.0% week · +11.1% month · +14.3% quarter · +26.9% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-02
  • Sovereign pressure Index -1.63 · down 2.22 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-02
How it trades on rate days beta 0.32 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How BBIO has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.32 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), BridgeBio Pharma Inc moved 0.32% on average · correlation 0.07 · higher than 23% of US names
  • Beta, last 3 months 0.56 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.81% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.87% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against BBIO on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — BridgeBio Pharma Inc

BBIO in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency. Several other drugs sit in Phase 3 trials, including treatments for achondroplasia, a calcium-related hormonal disorder and a muscular condition, alongside an early-stage gene therapy for Canavan disease. It works through licensing deals with larger pharmaceutical partners. It is based in Palo Alto, California.
Where it sits in the stack
BridgeBio Pharma has no seat in our index; it sits in the Healthcare sleeve of the diary's US universe, grouped there by sector and country rather than by any AI build-out layer.
Who it is priced against
Closelooknet's peer group here is scored Healthcare names based in the US, among them argenx, Medpace, BeiGene, Regeneron, Vertex and Corcept Therapeutics; the market also names Alnylam Pharmaceuticals as a comparison in genetic-disease drug development.
Why Closelooknet tracks it
BridgeBio Pharma carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.
What the diary watches
Whether the Phase 3 programmes for achondroplasia, the hormonal disorder and the muscular condition report results, since trial outcomes would reset the momentum reading.

BridgeBio Pharma Inc (BBIO) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 35/100 composite (momentum 49, quality 21, valuation 11) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 3 analyst actions on the wire · latest: price target by Morgan Stanley, 2026-10-21

The Street on this name

Analyst actions and the latest print for BBIO from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Morgan Stanley — target 87 from 97 Target cut to $87 from $97 (+28.7% to spot) 2026-10-21
  • Price target Piper Sandler — target 120 from 115 Target raised to $120 from $115 (+80.8% to spot) 2026-10-19
  • Price target Mizuho — target 110 from 96 Target raised to $110 from $96 (+43.6% to spot) 2026-09-01

3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 48 m USD in FY2025

Dividends and capital return

What BBIO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 48 m USD 0.3% of today's market value
  • Share count +6.0% in FY2025 133 m USD of stock-based compensation in the year
  • Capital returned 48 m USD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-03

Quick answers

What is BridgeBio Pharma Inc (BBIO)?

BridgeBio Pharma Inc trades as BBIO on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-03.

Is BBIO in a Closelooknet index?

Not currently — BridgeBio Pharma Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-03.

What is BridgeBio Pharma Inc's Closelooknet composite score?

35 out of 100, with momentum 49, quality 21 and valuation 11 sub-scores, as of 2026-11-03. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does BBIO trade against its moving averages?

BridgeBio Pharma Inc trades 6.9% above its 50-day and 3.1% above its 200-day moving average (10.3% above its 20-day). As of 2026-11-02 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does BridgeBio Pharma Inc compare with its peers?

Against its peer group (Biotechnology · US), BridgeBio Pharma Inc (BBIO) sits 19.7% below its 52-week high, 6.9% above its 50-day average; Halozyme Therapeutics Inc (HALO) is 3.8% below, BeiGene, Ltd. (ONC) is 7.0% below, argenx NV ADR (ARGX) is 18.4% below, as of 2026-11-02. Put any of them next to BBIO in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does BridgeBio Pharma Inc trade when bond yields rise?

Over the past year BridgeBio Pharma Inc had a beta of 0.32 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 23% of US names. On the 10 sessions in which long bonds fell most it moved −1.81% on average, against −0.74% for the S&P 500. As of 2026-11-02; The "How it trades on rate days" block on this page carries the lines.

What does BridgeBio Pharma Inc do?

BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency. Several other drugs sit in Phase 3 trials, including treatments for achondroplasia, a calcium-related hormonal disorder and a muscular condition, alongside an early-stage gene therapy for Canavan disease. Closelooknet's peer group here is scored Healthcare names based in the US, among them argenx, Medpace, BeiGene, Regeneron, Vertex and Corcept Therapeutics; the market also names Alnylam Pharmaceuticals as a comparison in genetic-disease drug development. (Company snapshot of 2026-09-17.)

Where does BridgeBio Pharma Inc sit in the AI build-out?

BridgeBio Pharma has no seat in our index; it sits in the Healthcare sleeve of the diary's US universe, grouped there by sector and country rather than by any AI build-out layer. BridgeBio Pharma carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it. (Company snapshot of 2026-09-17.)

Does BridgeBio Pharma Inc pay a dividend?

No cash distribution shows in BridgeBio Pharma Inc’s price series over the last three years. In fiscal 2025 the company bought back 48 m USD of its own shares. The share count rose 6.0% over the fiscal year. As of 2026-11-02; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on BridgeBio Pharma Inc recently?

The most recent analyst action on BridgeBio Pharma Inc on the Closelooknet wire is a price target by Morgan Stanley on 2026-10-21 (target 87 from 97). 3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BBIO, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.